Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire.
The FTC’s unconditional clearance of the move “is another significant milestone in the transaction process,” the firm said.
Takeda announced plans to buy Shire in a deal valued at around £46 billion back in May, ranking as one of the industry’s biggest.
“Shire’s highly complementary product portfolio and pipeline, as well as experienced employees, will accelerate our transformation for a stronger Takeda,” said Takeda’s chief executive Christophe Weber, explaining the move.
“Together, we will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies.”
The acquisition remains subject to a number of conditions, including receipt of other regulatory clearances and approval by the shareholders of both companies.
By Selina McKee
Source: Pharma Times
AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and predictive data analysis, according to a GlobalData survey. The leading data and analytics company’s report, “The State of the Biopharmaceutical Industry – 2025,” highlights AI’s potential to boost productivity and cut costs in the coming year.
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as atopic dermatitis, asthma, and COPD.
While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes as the first closed-loop therapy approach—allowing for self-adjusting neuromodulation in real time to help control the condition’s motor symptoms.
